Evidence map›Paper›PMID 29364834›Full record

ArticleMolecules (Basel, Switzerland)2018

Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells.

Ho Bong Hyun, Jeong Yong Moon, Somi Kim Cho

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Effect of Quercetin on ABCC6 Transporter: Implication in HepG2 Migration.International journal of molecular sciences · 2021
    Article
  17. Article
  18. Article
  19. Methanol Extract of Aerial Parts ofMolecules (Basel, Switzerland) · 2019
    Article
  20. Controlling metastatic cancer: the role of phytochemicals in cell signaling.Journal of cancer research and clinical oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ho Bong HyunFaculty of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Korea. fhdighqhd@nate.com.
Jeong Yong MoonSubtropical/Tropical Organism Gene Bank, Jeju National University, Jeju 63243, Korea. owenmjy@jejunu.ac.kr.
Somi Kim ChoFaculty of Biotechnology, College of Applied Life Sciences, SARI, Jeju National University, Jeju 63243, Korea. somikim@jejunu.ac.kr.
Jeju National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cysteine-rich angiogenic inducer 61 (CYR61) is an extracellular matrix-associated protein involved in survival, tumorigenesis, and drug resistance. Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC). Among the tested flavones, quercetin had the lowest 50% inhibitory concentration (IC

Indexed as

AdenocarcinomaAntineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalCysteine-Rich Protein 61Drug Resistance, MultipleDrug Resistance, NeoplasmDrug SynergismEpithelial-Mesenchymal TransitionFluorouracilHumansInhibitory Concentration 50QuercetinAntineoplastic AgentsCCN1 protein, humanCysteine-Rich Protein 61FluorouracilQuercetinapoptosisCYR61multidrug resistance (MDR)quercetinsynergistic effect

Identifiers

PMID29364834
PMCPMC6017870
OpenAlexW2789035736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.